Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2024-03-21 Regulatory Filings
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer
Regulatory Filings Classification · 99% confidence The document is titled "Company Announcement" and details the "Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer." It summarizes clinical trial results, mentions future presentation plans ("Nykode will present detailed data in a future scientific publication and at a forthcoming conference"), and provides general company and trial background. This structure—a press release announcing key clinical/financial updates without being the full, detailed report itself—is characteristic of an Earnings Release (ER) or a general announcement. Since the content is focused on clinical trial results and not quarterly financial performance highlights, it is best classified as a general announcement that doesn't fit the specific financial report categories (10-K, IR, ER). Given the options, it functions as a high-level update intended for investors and the public. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal regulatory filing like 10-K or AR. It is a press release announcing scientific progress. The closest fit among the provided codes for a general, non-financial, high-level announcement that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for miscellaneous announcements, or potentially an Earnings Release (ER) if we interpret 'topline conclusions' broadly, but ER usually implies financial results. Since it is a scientific/clinical update announcement, RNS is the most appropriate fallback for a non-standard announcement type.
2024-03-21 English
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer
Regulatory Filings Classification · 99% confidence The document is a press release from Nykode Therapeutics announcing 'Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial'. It details clinical trial results, future development plans (including a potential US pivotal trial C-04), and states that detailed data will be presented in a 'future scientific publication and at a forthcoming conference'. This structure—announcing key results and stating that the full details will follow in a formal report or presentation—is characteristic of an Earnings Release (ER) or a general press release summarizing significant operational/clinical news. Since it is focused purely on clinical trial results and future development strategy rather than comprehensive financial performance for a period, and it is not a transcript, a formal regulatory filing like 10-K, or a specific announcement like a dividend or management change, the most appropriate classification is Earnings Release (ER), as clinical trial updates often accompany or substitute for quarterly financial reporting in biotech, or it could be classified as a Regulatory Filing (RNS) if it were less focused on results. Given the focus on 'Topline Conclusions' and the announcement of future presentation of detailed data, ER is a strong fit for a major clinical update, but since it is not explicitly tied to a fiscal quarter's financial results, and it is a general announcement of clinical progress, it fits best under the general announcement category if ER is too specific to financials. However, in the context of biotech, major clinical updates are often released as ERs. Let's re-evaluate against the definitions. It is not a 10-K, AR, CT, or IP. It is an announcement of results. Since it is a press release announcing clinical trial results and future plans, and not a formal financial report, it is best classified as an Earnings Release (ER) if it is the primary communication of period performance/progress, or RNS if it's just a general update. Given the significance of the data update, ER is often used for such announcements in this sector. If we strictly follow the definitions, it is a major announcement of operational progress. Since it is not a formal report itself but an announcement of findings, and it is not a proxy statement (DEF 14A) or a management discussion (MDA), ER is the closest fit for a major periodic update, even if financial figures are absent. If it were purely a regulatory filing without the press release structure, RNS would be used. I will classify it as ER based on the nature of announcing 'topline conclusions' which often accompany or substitute for quarterly financial reporting in this industry.
2024-03-21 English
Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases
Regulatory Filings Classification · 99% confidence The document is titled "Company Announcement" and details scientific updates regarding Nykode Therapeutics' inverse vaccine platform presented at a specific industry summit (7th Antigen-Specific Immune Tolerance Drug Development Summit). It discusses preclinical data, scientific findings, and future potential, rather than releasing comprehensive periodic financial results (like 10-K or IR), announcing management changes (MANG), or reporting insider trades (DIRS). It is a general announcement about scientific progress and investor relations material, but it is not a formal Investor Presentation (IP) or a standard Earnings Release (ER). Since it is a specific announcement about scientific progress and updates shared at a conference, and it doesn't fit the strict definitions of the other categories, it falls best under the general Regulatory Filings category (RNS) as a miscellaneous corporate update, or potentially an Investor Presentation (IP) if the content was structured as a slide deck, but given the format, RNS is the most appropriate catch-all for non-financial, non-governance, non-legal specific corporate news.
2024-03-19 English
Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases
Regulatory Filings Classification · 99% confidence The document is a press release titled "Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases." It details scientific updates, preclinical data presentation at a summit, and mentions future plans. This format, announcing recent operational or scientific progress outside of mandatory periodic financial filings (like 10-K or IR), strongly suggests an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on scientific/platform updates rather than specific quarterly financial figures (which would point to ER or IR), and it is a formal announcement of company news, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release if it were tied to a specific reporting period's results. Given the content is primarily scientific advancement announcement, RNS is the most appropriate general regulatory category for non-standard announcements. However, press releases announcing scientific progress are often categorized as Earnings Releases (ER) if they are issued around reporting periods, or RNS if they are purely informational. Since it is a formal announcement of company news that doesn't fit the specific definitions of AR, 10-K, CT, etc., RNS is the safest fallback. Upon re-evaluation, many companies issue these scientific updates as part of their regular investor communications cadence, which often aligns with ERs or general news releases. Given the lack of specific quarterly financial numbers, RNS is the most accurate fit for a general regulatory announcement of scientific progress.
2024-03-19 English
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider
Director's Dealing Classification · 100% confidence The document text clearly details a transaction involving a person discharging managerial responsibilities (Harald Gurvin, Chief Financial Officer) in Nykode Therapeutics ASA. It specifies the nature of the transaction as 'Acquisition of shares', provides the price, volume, date (13.03.2024), and the place (XOSL - Oslo Stock Exchange). This structure is characteristic of mandatory insider trading disclosures, which fall under the category of Director's Dealing (DIRS) in the provided definitions.
2024-03-13 English
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider
Director's Dealing Classification · 99% confidence The document explicitly states it is a 'Mandatory notification of acquisition of shares by primary insider'. It details a transaction (acquisition of 10,000 shares) by the Chief Financial Officer (a primary insider). This directly corresponds to the definition of Director's Dealing (insider trades). Filing Definition Check: - AGM-R: No. - 10-K: No. - AR: No. - MANG: No, this is about trading, not management change. - CT: No. - CAP: No. - DVA: No. - DLST: No. - DIRS: Yes, 'Report of personal share transactions by company directors and executives (insider trades)'. - ER: No. - SR: No. - XLSX: No. - FS: No. - CGR: No. - IRAT: No. - IR: No. - IP: No. - LTR: No. - TAR: No. - MRQ: No, this is an individual insider trade, not a major shareholder threshold crossing. - MDA: No. - NAV: No. - DIV: No. - PSI: No. - RNS: No, DIRS is more specific. - DEF 14A: No. - RPA: No, although it mentions an 'attached document', the core content is the insider trade notification itself, making DIRS the primary classification. - SHA: No. - POS: No, this is an insider trading report, not a general share repurchase program announcement. The classification is DIRS.
2024-03-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.